Ivy Altomare
Hematology & Oncology · Durham, NCNPI 1609063254
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (44.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Incyte Corporation at 53.2% of the total. Reporting peaked in 2019 at $103,826 and has fallen 99.4% since, to $580 in 2024. Among hematology & oncology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $766.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$87K
- Amgen$23K
- Novartis$20K
- Rigel Pharmaceuticals, Inc.$19K
- Dova Pharmaceuticals$8K
- Pfizer$6K
- plus $1K from 12 others
Across 106 payments — averaging $1785.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$124K
- Pfizer$57K
- Rigel Pharmaceuticals, Inc.$9K
What the payments were for
- Consulting fees$71,69844%
- Speaking & faculty fees$73,38745%
- Travel & lodging$15,63310%
- Food & beverage$3,2342%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 88 | $87,238 |
| Amgen | 14 | $23,230 |
| Novartis | 19 | $19,983 |
| Rigel Pharmaceuticals, Inc. | 30 | $18,803 |
| Dova Pharmaceuticals | 6 | $7,777 |
| Pfizer | 13 | $5,542 |
| Merck | 3 | $609 |
| Genentech USA, Inc. | 19 | $261 |
| Foundation Medicine, Inc. | 1 | $229 |
| AstraZeneca | 6 | $83 |
| EMD Serono, Inc. | 6 | $73 |
| Exelixis Inc. | 2 | $26 |
| Bristol Myers Squibb | 1 | $25 |
| Lexicon Pharmaceuticals, Inc. | 2 | $24 |
| Johnson & Johnson | 1 | $18 |
| Sanofi | 1 | $18 |
| Bayer | 1 | $12 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$163,964 in reported general payments places this provider in the 95th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Durham
- Michael MorseDurham$2.6M
- Phillip FebboDurham$749K
- Matthew McKinneyDurham$277K
- Taewoong ChoiDurham$207K
- Jeffrey CrawfordDurham$125K
- Carlos de CastroDurham$124K
- Joseph MooreDurham$97K
- Ammon FagerDurham$56K
- Jameel MuzaffarDurham$31K
- Jeremy ForceDurham$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.